Lupin Partners With Fuji Pharma Subsidiary On “Nextstellis” Birth Control Pill

Lupin Limited has entered into a licensing and supply agreement with OLIC Limited (Thailand), which is a subsidiary of the Japanese pharmaceutical firm named as Fuji Pharma Co Ltd. This agreement came to terms to distribute

“Nextstellis” (drospirenone and estetrol tablets), in Vietnam and the Philippines. Nextstellis, a combined oral contraceptive pill, is unique in its formulation, containing a novel estrogen, estetrol (E4), in combination with drospirenone. Estetrol is a naturally occurring estrogen that is produced during pregnancy, which offers a distinct safety profile and is developed to provide effective contraception with less side effects. The pill has garnered attention for its potential to meet the diverse needs of women seeking reliable birth control options with minimal hormonal impact.Fabrice Egros, Lupin President (Corporate Development & Growth Markets) said in a statement, “The latest addition to Lupin’s women’s health portfolio will bolster the company's global healthcare expansion plans.” 

In addition, Fuji is a company listed on the Tokyo Stock Exchange that specializes in the production and sale of prescription pharmaceuticals. Their primary focus is on women's healthcare, offering generic medications for conditions such as menopausal disorders, infertility, contraception, dysmenorrhea, endometriosis, and many more.